About Us

Cellesce was founded in 2013 and is built on biochemical and bioprocess engineering expertise from the University of Bath and cell and organoid biology expertise from Cardiff University. In December 2017 Cellesce moved into the Medicentre in Cardiff, Wales.

Cellesce is a Biotech company that has developed a new patented bioprocessing technology for the growing and expansion of organoids. Organoids are a 3D cell structures with organ-like characteristics grown from stem cells. The Company is currently commercialising organoid models that are a powerful new enabling technology in drug discovery and genetics research.

The Lab Team

Cellesce Lab Team

The Cellesce Lab Team (from left to right) Dr Mairian Thomas, Professor Trevor Dale, Dr Marianne Ellis, Elizabeth Fraser, Dr Kim Luetchford

The Board

Our leadership team combines technical expertise in bioprocessing and the cancer biology of organoids together with a track record of incubating high potential start-ups and building businesses:

Mark Treherne


Mark obtained his PhD in pharmacology from Cambridge University and then developed novel 3D tissue culture models, as an academic at the University of Basel until 1992. He has over 25 years’ experience in the discovery of novel treatments for diseases with unmet medical need.

Mark formerly worked at Pfizer where he was responsible for research into neurodegenerative diseases, including using stem-cell derived lines for screening compounds. In 1997, Mark set up Cambridge Drug Discovery as Chief Executive, which was then sold to BioFocus (now part of Charles River) in 2001. Since then, Mark has worked with many early-stage biotechnology companies from foundation through to trade sale.‎More recently, hewas Chief Executive of the Life Sciences Organisation of UK Trade & Investment, which helped UK-based Life Sciences companies raise investment and export overseas.

Julian Chaudhuri

Director of Bioprocessing

Professor Julian Chaudhuri is a leading authority in regenerative medicine bioprocessing, and is currently Deputy Vice-Chancellor (Education) at the University of Plymouth. He was co-founder of Bath’s Centre for Regenerative Medicine in 2003, and is a member of the editorial board of the journal Regenerative Medicine.

Marianne Ellis


Dr Marianne Ellis is an expert in the design of bioprocesses for cell therapies, particularly scalable bioreactors for cell expansion. She is currently Senior Lecturer in the Department of Chemical Engineering at the University of Bath, UK. Marianne is a Royal Academy of Engineering/The Leverhulme Trust Senior Research Fellow, and has been selected as an EPSRC Rising Star.

Trevor Dale

Director of Organoid Biology

Professor Trevor Dale of Cardiff University is a pioneering research scientist interested in how cells talk to each other, how this goes wrong in cancer – and how protein machines control it all. The main focus of Trevor’s research group is on the Wnt signalling pathway, and his team are growing normal and tumour organoids from a number of human tissue types.

Trevor studied Biochemistry at Imperial College before completing a PhD on interferon signal transduction at the Imperial Cancer Research Fund (now Cancer Research UK). Following a postdoctoral fellowship at Baylor College of Medicine in Houston, he established a research group at the Institute of Cancer Research in London in 1991.

Nicholas Duggan


Nicholas is a partner in Viadynamics, a leading innovation consulting business, and has extensive experience leading and supporting start-up businesses. Nicholas also has over fifteen years of experience in accelerating and de-risking innovation across the medical, consumer, technology and service sectors.

He has a business studies degree and a master’s degree in business strategy, both from University College Dublin.

Rob Snedden


Rob is an experienced finance professional and has worked as financial controller for a number of companies. Robert graduated from Napier University, Edinburgh with a degree in Accounting and a Postgraduate Diploma in Industrial Administration. He became a member of CIMA in 1991.

John Allbrook


John is an experienced leader in global corporations, private equity and listed businesses across the financial services, business services and technology sectors. Most recently he was Chairman of Syscap, a specialist SME finance company. Previously he was the CEO of GoIndustry plc, the AIM listed provider of asset sales and valuation services. This followed a 10 year spell at GE Capital, where he led multiple P&Ls in Europe.

John’s proven expertise is in helping businesses to thrive in any economic environment, with an emphasis on building robust financial, strategic, people and technology foundations to enable profitable growth.

Mark Cole

Non-Executive Director

Mark is an experienced investor and advisor who previously led, built and sold businesses on an international scale in his executive career as a merchant banker.  He has demonstrable skills in developing strategies, structures. processes and business plans which are deliverable and financeable. He also has proven expertise in change management and mentoring.

William Allbrook

Marketing Director

William is a marketing consultant to technology-rich businesses, specialising in SMEs and start-ups. Prior to this he worked for Corporate Identity consultants Wolff Olins and spent seven years growing a start-up company.

Francis Bealin-Kelly

Non-Executive Director

Francis is an innovation and R&D leader with a proven track record of building high performing teams that build businesses. He is currently a Member of Executive Committee and Chief Technology Officer at Strauss Coffee, and was previously Head of Research & Development and Technical Innovation at SABMiller.

Chris Thompson

Non-Executive Director

With a background in physics, engineering and accountancy, Chris has spent 25 years working in design and innovation consulting. He was Chief Operator Officer of Fitch plc working in the US and UK and MD of PSD Associates Ltd before founding Viadynamics in 1998.

Viadynamics advises businesses on how to make innovation happen – from strategy to action including innovation capability building. Chris has led innovation assignments for global corporations (like 3M, Abbott, AXA, Fresenius, GSK, Leo Pharma, Mars, Pepsico, SABMiller and Unilever), start-ups (like Snap Fashion, and Sugru), and for universities (Cambridge, Kent, Warwick and York).

© Cellesce Ltd 2018